Physician profile
Matthew B Bailey
NPI 1386878080
$13,116.85
in general payments reported to CMS, 2019-2025
31 companies · $68.74 in 2025
The $68.74 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.93 · 2020: $15.53 · 2021: $9,071 · 2022: $3,184 · 2023: $331 · 2024: $397 · 2025: $68.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,879.25 | 2021-2022 | |
| Axonics, INC. | $293.08 | 2022-2024 | Axonics |
| Allergan, INC. | $123.84 | 2021-2022 | |
| Davol INC. | $113.02 | 2022-2023 | Phasix Mesh |
| Boston Scientific Corporation | $64.55 | 2022 | |
| 180 Medical, INC. | $55.17 | 2023 | |
| Braintree Laboratories, INC. | $43.97 | 2020-2023 | Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $38.70 | 2022-2023 | Gattex |
| Abbvie INC. | $38.34 | 2023 | Natrelle Saline-Filled Breast Implants, Qulipta, Ubrelvy |
| Enterra Medical, INC. | $33.87 | 2025 | |
| Procept Biorobotics Corporation | $32.91 | 2023 | Aquabeam Robotic System |
| Smith+Nephew, INC. | $32.83 | 2024 | Pico 14, Pico 7, Renasys Touch |
| Pacira Pharmaceuticals Incorporated | $28.86 | 2022-2023 | Exparel |
| Ethicon US, LLC | $27.67 | 2023 | Enseal |
| Sumitomo Pharma America, INC. | $26.49 | 2023 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $26.01 | 2024 | |
| Ascensia Diabetes Care US INC. | $23.40 | 2024 | |
| Endogastric Solutions, INC | $23.08 | 2023 | Esophyx |
| Kerecis Limited | $22.07 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Solventum Corporation | $20.35 | 2025 | V.A.C. Veraflo, Prevena |
| Lsi Solutions INC | $19.10 | 2019 | |
| Next Science LLC | $17.90 | 2019 | |
| Endomagnetics LTD | $17.27 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.15 | 2023 | Strensiq |
| Ambu INC. | $14.81 | 2022 | |
| Medtronic, INC. | $14.76 | 2023 | Bravo |
| Vertex Pharmaceuticals Incorporated | $14.52 | 2025 | |
| Polynovo North America LLC | $14.08 | 2024 | Novosorb Btm |
| Teleflex LLC | $13.93 | 2019 | |
| Angiodynamics, INC. | $13.12 | 2024 | Nanoknife |
| Conmed Corporation | $12.75 | 2023 | Airseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.